3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Recruiting
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
23
Carcinoma, Non-Small-Cell Lung
4
Liver Neoplasms
3
Pancreatic Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Liver Cirrhosis
1
Hepato Cellular Carcinoma
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Nivolumab
11
Oxaliplatin
6
Fluorouracil
6
Capecitabine
5
pembrolizumab
4
Paclitaxel
4
Leucovorin
4
durvalumab
3
Radiotherapy
3
Folfox protocol
3
Drug Therapy
3
dehydroftorafur
2
Trastuzumab
2
Specimen Handling
2
Radiation
2
Metformin
2
Magnetic Resonance Spectroscopy
2
Itraconazole
2
Irinotecan
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
zolbetuximab
1
zanidatamab
1
trifluridine tipiracil drug combination
1
tremelimumab
1
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adenocarcinoma Of Esophagus
×
tremelimumab
×
Clear all
NCT03539822
2026-01-21
CAMILLA
University of Pittsburgh
Phase 1/2
Recruiting
117 enrolled